Buy | Dcth Stock

: The company currently operates 28 active treatment centers and plans to expand to 40 centers by the end of 2026 .

is currently positioned as a high-growth medical device company, with a consensus "Moderate Buy" or "Strong Buy" rating from Wall Street analysts. The company reached a financial turning point in 2025, recording its first year of net income and record-high revenues. Investment Thesis: Why Buy? buy dcth stock

: Management expects at least $100 million in revenue for fiscal year 2026. Projections suggest the company will return to profitability (estimated EPS of $0.04) by Q2 2026. : The company currently operates 28 active treatment

: Results from the CHOPIN Phase 2 trial showed significant survival improvements for liver treatment, which may support broader adoption and inclusion in clinical guidelines. Financial Snapshot & Market Performance Google's Finance Data Investment Thesis: Why Buy

: Delcath reported record 2025 revenue of $85.2 million , a significant increase from $37.2 million in 2024. This was primarily driven by its HEPZATO KIT , which saw a 144% year-over-year sales surge .